{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:15:55Z","timestamp":1783350955891,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.avsg.2026.04.044","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:25:19Z","timestamp":1778552719000},"page":"282-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-9836","authenticated-orcid":false,"given":"Judith A.H.M.","family":"Peeters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap F.","family":"Hamming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.A.","family":"Quax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2026.04.044_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.avsg.2026.04.044_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1078-5884(11)60009-9","article-title":"Chapter I: definitions, epidemiology, clinical presentation and prognosis","volume":"42","author":"Becker","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2026.04.044_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","article-title":"Peripheral arterial disease in patients with diabetes","volume":"47","author":"Marso","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2026.04.044_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110194","article-title":"Global estimates of diabetes-related amputations incidence in 2010-2020: a systematic review and meta-analysis","volume":"195","author":"Ezzatvar","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.avsg.2026.04.044_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/SLA.0000000000002896","article-title":"No clinical benefit of intramuscular delivery of bone marrow-derived mononuclear cells in nonreconstructable peripheral arterial disease: results of a Phase-III randomized-controlled trial","volume":"268","author":"Lindeman","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.avsg.2026.04.044_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.114.012913","volume":"131","author":"Teraa","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.044_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCINTERVENTIONS.110.958348","article-title":"Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA)","volume":"4","author":"Walter","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2026.04.044_bib8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3727\/096368910X0177","article-title":"Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia","volume":"20","author":"Ruiz-Salmeron","year":"2011","journal-title":"Cel Transpl"},{"key":"10.1016\/j.avsg.2026.04.044_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","article-title":"Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial","volume":"360","author":"Tateishi-Yuyama","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2026.04.044_bib10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.116.309045","article-title":"Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies","volume":"120","author":"Rigato","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.avsg.2026.04.044_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","article-title":"Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia","volume":"118","author":"Powell","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.04.044_bib12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.avsg.2026.04.044_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1253\/circj.CJ-17-0045","article-title":"Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia - results of a randomized, double-blind, placebo-controlled trial","volume":"81","author":"Pignon","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.avsg.2026.04.044_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jvir.2020.09.003","article-title":"Randomized, double-blind, placebo-controlled trial to evaluate safety and therapeutic efficacy of angiogenesis induced by intraarterial autologous bone marrow-derived stem cells in patients with severe peripheral arterial disease","volume":"32","author":"Sharma","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.avsg.2026.04.044_bib15","article-title":"Therapeutic angiogenesis for patients with chronic limb-threatening ischemia: promising or hoax?","volume":"6","author":"Peeters","year":"2024","journal-title":"Vasc Biol"},{"key":"10.1016\/j.avsg.2026.04.044_bib16","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2026.04.044_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/sctm.18-0025","article-title":"Cell therapy for chronic limb-threatening ischemia: current evidence and future directions","volume":"7","author":"Teraa","year":"2018","journal-title":"Stem Cell Transl Med"},{"key":"10.1016\/j.avsg.2026.04.044_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-024-02393-z","article-title":"Autologous cell therapy for ischemic diabetic foot: a meta-analysis of randomized controlled trials for the development of the Italian guidelines for the treatment of diabetic foot syndrome","author":"Scatena","year":"2024","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.avsg.2026.04.044_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2023.11.001","article-title":"Compelling evidence from meta-epidemiological studies demonstrates overestimation of effects in randomized trials that fail to optimize randomization and blind patients and outcome assessors","volume":"165","author":"Wang","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.avsg.2026.04.044_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111787","article-title":"Empirical evidence of observer bias in randomized clinical trials: updated and expanded analysis of trials with both blinded and non-blinded outcome assessors","volume":"183","author":"Salazar","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.avsg.2026.04.044_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52274","article-title":"Discordant information on blinding in trial registries and published research: a systematic review","volume":"7","author":"Zhang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2026.04.044_bib22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0003319715595172","article-title":"Cell therapy for critical limb ischemia: a meta-analysis of randomized controlled trials","volume":"67","author":"Liew","year":"2016","journal-title":"Angiology"},{"key":"10.1016\/j.avsg.2026.04.044_bib23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcyt.2020.03.432","article-title":"What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings","volume":"22","author":"Ten Ham","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.avsg.2026.04.044_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111536","article-title":"Resource use and costs of investigator-sponsored randomized clinical trials in Switzerland, Germany, and the United Kingdom: a metaresearch study","volume":"176","author":"Griessbach","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.avsg.2026.04.044_bib25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/rme-2019-0066","article-title":"Publication rates and reported results in a cohort of gene- and cell-based therapy trials","volume":"15","author":"Coppens","year":"2020","journal-title":"Regen Med"},{"key":"10.1016\/j.avsg.2026.04.044_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.24440","article-title":"Nonregistration, discontinuation, and nonpublication of randomized trials: a systematic review","volume":"8","author":"Speich","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2026.04.044_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003980","article-title":"Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis","volume":"19","author":"Speich","year":"2022","journal-title":"Plos Med"},{"key":"10.1016\/j.avsg.2026.04.044_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237464","article-title":"Funders' data-sharing policies in therapeutic research: a survey of commercial and non-commercial funders","volume":"15","author":"Gaba","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2026.04.044_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1740774519865517","article-title":"Transparency and objectivity in governance of clinical trials data sharing: current practices and approaches","volume":"16","author":"Shabani","year":"2019","journal-title":"Clin Trials"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626002839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626002839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:37:18Z","timestamp":1783348638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509626002839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0890509626002839"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2026.04.044","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2026.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}